Reed M L, Vaitkevicius V K, Al-Sarraf M, Vaughn C B, Singhakowinta A, Sexon-Porte M, Izbicki R, Baker L, Straatsma G W
Cancer. 1981 Jan 15;47(2):402-9. doi: 10.1002/1097-0142(19810115)47:2<402::aid-cncr2820470231>3.0.co;2-b.
Ten-year results are presented of 124 patients with malignancy apparently limited to the distribution of the hepatic artery, treated to prospective protocol with continuous infusion of 5-FUdR through an hepatic artery catheter. Nearly all patients had moderate to massive hepatic replacement. Of 88 patients with colorectal carcinoma, 64 (73%) had clinically objective and subjective remission. Median survival for responders was 13 months; for the entire group, ten months. Of 13 patients with hepatoma, nine had clinically significant regression with a median survival of 11 months. Ten patients had carcinoma of the gall bladder or bile duct with seven obtaining clinically significant regression. Complications encountered are discussed and are similar to other series. Of the patients experiencing clinically significant remission, all but one reached the complete independence performance status, and 84% reached normal activity levels. Thus, for hepatic localized tumor, this therapy is worthwhile and practical.
本文呈现了124例恶性肿瘤明显局限于肝动脉分布区域的患者的十年研究结果,这些患者按照前瞻性方案通过肝动脉导管持续输注5-氟脱氧尿苷进行治疗。几乎所有患者都有中度至重度的肝脏替代。88例结直肠癌患者中,64例(73%)有临床客观和主观缓解。缓解者的中位生存期为13个月;整个组为10个月。13例肝癌患者中,9例有临床显著消退,中位生存期为11个月。10例胆囊或胆管癌患者中有7例有临床显著消退。文中讨论了所遇到的并发症,这些并发症与其他系列相似。在有临床显著缓解的患者中,除1例之外全部达到完全独立的功能状态,84%达到正常活动水平。因此,对于肝脏局限性肿瘤,这种治疗是值得且实用的。